426 related articles for article (PubMed ID: 37483659)
1. Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors.
Neeser A; Ramasubramanian R; Wang C; Ma L
Immunooncol Technol; 2023 Sep; 19():100385. PubMed ID: 37483659
[TBL] [Abstract][Full Text] [Related]
2. CAR-T cells: Early successes in blood cancer and challenges in solid tumors.
Dana H; Chalbatani GM; Jalali SA; Mirzaei HR; Grupp SA; Suarez ER; Rapôso C; Webster TJ
Acta Pharm Sin B; 2021 May; 11(5):1129-1147. PubMed ID: 34094824
[TBL] [Abstract][Full Text] [Related]
3. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
Roselli E; Faramand R; Davila ML
J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T-Cell Therapy: Reach to Solid Tumor Experience.
Metzinger MN; Verghese C; Hamouda DM; Lenhard A; Choucair K; Senzer N; Brunicardi FC; Dworkin L; Nemunaitis J
Oncology; 2019; 97(2):59-74. PubMed ID: 31261152
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
6. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
Zhang C; Zhuang Q; Liu J; Liu X
ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
[TBL] [Abstract][Full Text] [Related]
7. Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system.
Wang X; Wu Z; Qiu W; Chen P; Xu X; Han W
Front Med; 2020 Dec; 14(6):726-745. PubMed ID: 32794014
[TBL] [Abstract][Full Text] [Related]
8. CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success.
Long KB; Young RM; Boesteanu AC; Davis MM; Melenhorst JJ; Lacey SF; DeGaramo DA; Levine BL; Fraietta JA
Front Immunol; 2018; 9():2740. PubMed ID: 30559740
[TBL] [Abstract][Full Text] [Related]
9. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
10. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
11. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
Shum T; Kruse RL; Rooney CM
Expert Opin Biol Ther; 2018 Jun; 18(6):653-664. PubMed ID: 29727246
[TBL] [Abstract][Full Text] [Related]
12. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
13. Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.
Titov A; Valiullina A; Zmievskaya E; Zaikova E; Petukhov A; Miftakhova R; Bulatov E; Rizvanov A
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31947775
[TBL] [Abstract][Full Text] [Related]
14. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
15. Innovative strategies to advance CAR T cell therapy for solid tumors.
Huang M; Deng J; Gao L; Zhou J
Am J Cancer Res; 2020; 10(7):1979-1992. PubMed ID: 32774996
[TBL] [Abstract][Full Text] [Related]
16. In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors.
Sun Z; Li R; Shen Y; Tan S; Ding N; Xu R; Wang X; Wei J; Liu B; Meng F
J Hematol Oncol; 2022 Mar; 15(1):29. PubMed ID: 35303900
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications.
Mirzaei HR; Rodriguez A; Shepphird J; Brown CE; Badie B
Front Immunol; 2017; 8():1850. PubMed ID: 29312333
[TBL] [Abstract][Full Text] [Related]
18. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
19. Current Progress in CAR-T Cell Therapy for Solid Tumors.
Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q
Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328
[TBL] [Abstract][Full Text] [Related]
20. Application of CAR T cells for the treatment of solid tumors.
Khan JF; Khan AS; Brentjens RJ
Prog Mol Biol Transl Sci; 2019; 164():293-327. PubMed ID: 31383408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
